Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis

Autor:	A. Wang, Rachel B. Wagman, S. Adami, Santiago Palacios, L. Kalouche-Khalil, C. Zapalowski, Jonathan D. Adachi, René Rizzoli, J. C. Gallagher, R. G. Feldman, David L. Kendler, Heinrich Resch
Rok vydání:	2015
Předmět:	Fracture risk medicine.medical_specialty Osteoporosis Postmenopausal osteoporosis Placebo Fragility Double-Blind Method Bone Density Recurrence Risk Factors medicine Humans Osteoporosis Postmenopausal Aged Bone mineral Aged 80 and over Lumbar Vertebrae Bone Density Conservation Agents business.industry Hip Fractures Incidence Age Factors Obstetrics and Gynecology General Medicine Middle Aged medicine.disease Surgery Denosumab ddc:618.97 Population study Spinal Fractures Female business medicine.drug
Zdroj:	Climacteric, Vol. 18, No 6 (2015) pp. 805-812
ISSN:	1473-0804 1369-7137
Popis:	Objectives A history of prior fracture is one of the strongest predictors of a future fragility fracture. In FREEDOM, denosumab significantly reduced the risk of new vertebral, non-vertebral, and hip fractures. We carried out a post-hoc analysis of FREEDOM to characterize the efficacy of denosumab in preventing secondary fragility fractures in subjects with a prior fracture.Methods A total of 7808 women aged 60–90 years with a bone mineral density T-score of less than − 2.5 but not less than − 4.0 at either the lumbar spine or total hip were randomized to subcutaneous denosumab 60 mg or placebo every 6 months for 36 months. The anti-fracture efficacy of denosumab was analyzed by prior fracture status, to assess secondary fragility fracture, and by subject age, prior fracture site and history of prior osteoporosis medication use.Results A prior fragility fracture was reported for 45% of the overall study population. Compared with placebo, denosumab significantly reduced the risk of a secondary fragility fracture by 39% (incidence, 17.3% vs. 10.5%; p < 0.0001). Similar results were observed regardless of age or prior fracture site. In the overall population, denosumab significantly reduced the risk of a fragility fracture by 40% (13.3% vs. 8.0%; p < 0.0001), with similar results observed regardless of history of prior osteoporotic medication use.Conclusions Denosumab reduced the risk of fragility fractures to a similar degree in all risk subgroups examined, including those with prior fragility fractures. Identifying and treating high-risk individuals could help to close the current care gap in secondary fracture prevention.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db51930daaad80ee3a7a742b4cf2b4ca https://pubmed.ncbi.nlm.nih.gov/26029985 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.